INOTREM
14.4.2022 08:02:08 CEST | Business Wire | Press release
Inotrem , an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD. The Crohn’s & Colitis Foundation is one of world’s largest and most influential non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis.
The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment. Inotrem will conduct this project in partnership with the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York. Under the terms of the agreement, Inotrem will access data and bio-samples from Foundation’s IBD Plexus® , which is the largest IBD database in the US with data from over 25,000 patients. The project is expected to last 18 months and will be a cornerstone in the design of Inotrem’s new drug candidate first-in-human clinical study.
There are today 10 million people worldwide suffering from IBD (Crohn’s disease and ulcerative colitis), a lifelong illness for which the medical need continues to be important despite improvement over the last 30 years. Approximately 30% of patients are primarily unresponsive to existing therapies and even among responders, up to 10% will lose their response to the drug every year.
For a decade, Inotrem has been pioneering the biology of TREM-1 as a regulator of the immune response in acute and chronic inflammatory diseases. TREM-1 has been reported as a likely contributor to IBD pathophysiology, and targeting this biological pathway could offer a new treatment option for IBD patients with immune dysregulation.
Sven Zimmermann, CEO of Inotrem, says: “We are looking forward to collaborating with such a recognized and well-respected organization as The Crohn’s & Colitis Foundation. The robustness and diversity of their IBD patient database is unparalleled and will allow for in-depth analysis of TREM-1 potential as a therapeutic target in IBD patients. This agreement marks the beginning a long and fruitful partnership”.
“We are dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life for those affected by these diseases,” said Dr. Caren Heller, Chief Scientific Officer for the Crohn’s & Colitis Foundation. “We are pleased to work with Inotrem, a company that has developed a strong scientific leadership around the TREM-1 pathway, and look forward to understanding the potential ways that the TREM-1 pathway may play a role in the treatment of inflammatory bowel disease.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005626/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Solid Performance in 20253.3.2026 14:41:00 CET | Press release
Growing Sales to US$15.3 Billion, Net Profit Increased to US$1.2 Billion Techtronic Industries Co. Ltd. (“TTI” or the “Company”) (stock code: HK:0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025. TTI delivered record sales of US$15.3 billion in 2025, growing 4.4% on a reported basis and 4.1% in local currency. Our two leading brands, MILWAUKEE and RYOBI, both delivered solid performances in 2025 with MILWAUKEE growing 7.9% and RYOBI growing 5.4% in local currency. TTI delivered record sales and earnings despite significant tariff headwinds, growing sales 4.4% to US$15.3 billion and net profit 6.8% to US$1.2 billion. Our Global MILWAUKEE business grew 8.1% on a reported basis with underlying sales rising 10.3% in local currency (excluding the discretionary suspension of certain second half promoti
Quectel and MediaTek Unveil Next Generation 5G-A and Wi-Fi 8 Intelligent CPE Reference Design at MWC 20263.3.2026 14:38:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of a new intelligent CPE reference design based on the MediaTek T930 platform, integrating 5G-Advanced and Wi-Fi 8 technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303124613/en/ Quectel and MediaTek unveil next generation 5G-A and Wi-Fi 8 intelligent CPE reference design at MWC 2026 The solution combines the high-performance 5G-A connectivity, intelligent reliability and advanced capabilities of the MediaTek T930 platform with Quectel’s deep expertise in the global Fixed Wireless Access (FWA) market. Moving beyond a simple focus on high speed, it delivers a fully integrated, all-in-one solution featuring exceptional performance, ultra-high stability, and intelligent network management. Designed for both residential and enterprise users, the solution enables transformative improvements in broadband access, mobile
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria3.3.2026 14:00:00 CET | Press release
Partnership marks a critical step toward clinical development of an AAV gene therapy using a base editing approach designed to target the genetic cause of Hutchinson-Gilford Progeria SyndromeForge Biologics will provide process development and manufacturing expertise to support gene therapy advancement led by world-renowned researchers Leslie Gordon, David Liu, and Francis Collins The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for children and young adults living with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. This press release features multimedia. View the full
PAX Unveils Long-Anticipated PAX FOUR, Its Most Powerful Dry Herb Vaporizer Yet3.3.2026 14:00:00 CET | Press release
Designed for denser vapor and immediate impact without combustion, FOUR delivers smoking-level intensity in a precision-engineered, portable device Nearly two decades after defining the category, PAX today announced the launch of PAX FOUR, the most powerful dry herb vaporizer in the company’s history. Built for consumers who want dense vapor and immediate impact without combustion, PAX FOUR delivers smoking-level intensity you can see and feel in a sleek, precision-engineered device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303740648/en/ PAX FOUR, the most powerful dry herb vaporizer in the company’s history. The cannabis vaporization category continues to grow as consumers shift away from smoking and combustion, yet many remain loyal to traditional smoking methods, often citing weak vapor, lack of intensity, and inconsistent performance from existing devices. PAX FOUR was engineered to change that — producing large
Riskified Announces Expansion of AI Agent Intelligence to Secure Native Merchant AI Shopping Assistants3.3.2026 14:00:00 CET | Press release
Amidst the growing adoption of native AI agents and chatbots on retail websites, Riskified leverages its unique data infrastructure to help merchants deploy highly personalized, secure AI shopping assistants Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced an expansion of its AI Agent Intelligence platform, positioning the company as the definitive shield for the next era of ecommerce. As merchants explore deploying their own native, conversational AI shopping assistants to elevate their customer experience, Riskified is ensuring that these new touchpoints are protected from sophisticated fraud and abuse. Retailers are heavily investing in bringing AI agents directly to their digital storefronts. Research from McKinsey & Company underscores this trend, noting that 82% of retail organizations have already launched generative AI pilots focused on reinventing customer service. As merchants build out their AI shopping assistants to offer deep perso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom